Company profile: Celcuity
1.1 - Company Overview
Company description
- Provider of oncology therapeutics and cellular analysis solutions, including gedatolisib, an investigational pan-PI3K/mTOR inhibitor for advanced breast cancer and metastatic castration-resistant prostate cancer; the CELsignia platform to measure signal transduction in live tumor cells and identify tumor drivers and potential first-in-class targeted therapies; and an Expanded Access Program for patients from closed clinical trials.
Products and services
- CELsignia Platform: A live-cell cellular analysis platform that measures signal transduction activity in tumor cells to identify tumor drivers and potential first-in-class targeted therapies
- Expanded Access Program: An investigational-medicine access program offering investigational medicines to patients who initially received them in a clinical trial that is no longer open
- Gedatolisib: An investigational-grade pan-PI3K/mTOR inhibitor being developed to treat advanced breast cancer and metastatic castration-resistant prostate cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Celcuity
Northern Biologics
HQ: Canada
Website
- Description: Provider of state-of-the-art antibody discovery targeting novel and challenging oncology and fibrosis targets, developing therapeutic antibody candidates derived from a phage display platform developed and refined by world-leading researchers at the University of Toronto.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northern Biologics company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
Totus Medicines
HQ: United States
Website
- Description: Provider of AI/ML-driven small-molecule drug discovery using innovative DNA-encoded covalent libraries. Offers the Totus Platform combining AI/ML, cellular analysis, and covalent chemistry for high-throughput genome-wide screening, plus an oncology pipeline including TOS-358, a PI3Kα inhibitor for breast, colorectal, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Totus Medicines company profile →
Cullinan Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics, including zipalertinib (CLN-081/TAS6417) for NSCLC with EGFR exon 20 insertion mutations in pivotal Phase 2b; CLN-619, an anti-MICA/B antibody tested with a checkpoint inhibitor for advanced solid tumors and multiple myeloma; CLN-049 for relapsed/refractory AML and MDS in Phase 1; and CLN-617, a collagen-binding IL-12/IL-2 fusion for advanced solid tumors, both as monotherapy and in combination with pembrolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cullinan Therapeutics company profile →
Alpheus Medical
HQ: United States
Website
- Description: Provider of a non-invasive sonodynamic therapy platform for solid body cancers that uses ultrasound to activate a cancer-targeting drug, including an SDT platform for outpatient treatment of recurrent high-grade gliomas and CV-01, an investigational drug-device using low-intensity, large-field ultrasound to target cancer cells across the brain hemisphere; CV-01 is in Phase 1 clinical trials for recurrent glioblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpheus Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Celcuity
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Celcuity
2.2 - Growth funds investing in similar companies to Celcuity
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Celcuity
4.2 - Public trading comparable groups for Celcuity
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →